The Biotech Data Stack: What Every Startup Needs Before Series A

Most biotech startups don't think about data infrastructure until it's a crisis. Here's what you actually need, what you don't, and how to build it for less than your monthly coffee budget.

The problem no one talks about until it's too late

Last year, a preclinical-stage biotech raised $15M in seed funding. Strong science, experienced team, promising target. Six months in, their lead biologist needed to revisit dose-response data from an early screening experiment. The problem: the postdoc who ran that experiment had left three months prior. The data lived on her MacBook, which had been wiped and reassigned. Some of the raw files were in a shared Google Drive folder called "Screening Data (OLD)." The analysis scripts were in a personal GitHub repo that was now private. The metadata describing which cell lines, which passage numbers, which concentrations — that was in a lab notebook on a shelf somewhere.

It took two scientists three weeks to reconstruct what should have been a five-minute lookup. They never fully recovered the original analysis parameters. When they presented updated results to their scientific advisory board, there was an uncomfortable footnote: "Historical data partially reconstructed."

This is not an unusual story. It is, in fact, the default outcome for biotech startups that treat data infrastructure as something to figure out later. And "later" usually arrives at the worst possible time: during due diligence, during an IND-enabling study, or when a key team member leaves.

The economics are brutal. Retrofitting a data system after 12-18 months of ad hoc data generation costs 5-10x what it would have cost to set it up properly on day one. Not because the technology is expensive — it isn't — but because the archaeological work of finding, cleaning, cataloging, and re-annotating scattered datasets is pure manual labor. And unlike most engineering problems, you can't parallelize it. The person who understands what "exp_042_final_v3_FIXED.csv" actually contains is usually one specific human being, and they may not work for you anymore.

The minimum viable data stack

The good news: what you need at the 5-15 person stage is remarkably simple. You don't need a platform. You don't need a vendor. You need four things, and you can set them all up in a single focused week.

Data storage: structured cloud storage with naming conventions

Start with a single S3 bucket (or Google Cloud Storage, or Azure Blob — it doesn't matter). What matters is the folder structure and naming convention. Here's what actually works for a 10-person biotech:

Top-level folders by data type:

• /raw/ — Untouched instrument output. Never modified after upload.
• /processed/ — Cleaned, normalized, analysis-ready datasets.
• /results/ — Figures, reports, final outputs.
• /protocols/ — SOPs, analysis scripts, pipeline configs.

Within each folder, use a consistent naming pattern:

{date}_{project}_{experiment-type}_{identifier}/

For example: /raw/2026-03-15_PROJ-ABX_dose-response_HEK293/

This costs about $20/month for a typical early-stage biotech generating a few hundred gigabytes of data. Compare that to the $2,000-5,000/month some startups spend on a data warehouse they don't need yet. The critical rule: raw data is immutable. Once uploaded, it is never overwritten, never modified, never deleted. If you reprocess it, the output goes in /processed/ with a reference back to the raw source. This one principle will save you from more data disasters than any tool you can buy.

Data catalog: start with a spreadsheet

A data catalog answers a simple question: "What data do we have, and where is it?" At five people, the right answer is a shared Google Sheet or Airtable base with the following columns:

• Dataset name — matches the folder name in S3
• Description — one-sentence summary of what this data represents
• Generated by — person who created the data
• Date generated
• Project — which program this belongs to
• Instrument/source — plate reader, flow cytometer, sequencer, etc.
• Storage path — full S3 path
• Status — raw, processed, archived
• Notes — anything unusual about this dataset

Yes, this is low-tech. That's the point. A spreadsheet that everyone actually uses beats a sophisticated data catalog platform that three people have logins to and nobody updates. The activation energy for adding a row to a spreadsheet is near zero. The activation energy for logging into a dedicated platform, navigating its UI, and filling out 15 required metadata fields is high enough that people just won't do it.

When you hit 15-20 people and the spreadsheet starts groaning, you graduate to a lightweight database — Airtable, a simple PostgreSQL instance, or a purpose-built tool like Benchling's registry. But that's a Series A problem. Don't solve it now.

Analysis environment: standardize once, save hundreds of hours

The single most common source of irreproducible results in computational biology is environment drift. Scientist A ran the analysis six months ago with pandas 1.5.3 and scikit-learn 1.2.0. Scientist B tries to reproduce it today with pandas 2.1.4 and scikit-learn 1.4.2. The results are different. Nobody knows why. Three days of debugging later, someone discovers that a default parameter changed between library versions.

The fix takes one afternoon:

• Create a standard Docker image with your team's core stack: Python 3.11, R 4.3, Jupyter, RStudio, and pinned versions of every package your team uses. Store the Dockerfile in version control.
• Pin everything. Not just major versions — pin to the patch level. numpy==1.26.4, not numpy>=1.26. Use requirements.txt for Python and renv.lock for R.
• Provide a one-command launch. docker compose up should give any team member a fully configured Jupyter or RStudio environment that is identical to everyone else's.

One afternoon of setup saves hundreds of hours of "it works on my machine." It also means that when a new scientist joins, they can be running analyses on day one instead of spending their first week installing packages and fighting dependency conflicts.

If Docker feels like overkill for your team, at minimum maintain a shared requirements.txt in a team repository and enforce that everyone uses it. Even that basic step eliminates 80% of reproducibility issues.

Backup and access control: the boring stuff that matters most

Three non-negotiable practices:

Automated backups. Enable S3 versioning so that every overwrite preserves the previous version. Set up cross-region replication for anything that would be catastrophic to lose. This costs pennies. A single failed hard drive containing unrecoverable assay data costs months of work.

Access control. Use IAM roles with the principle of least privilege. Scientists get read/write access to their project folders. Everyone gets read access to /raw/. Only designated admins can delete anything. This isn't about trust — it's about preventing accidents. The most common data loss event in early-stage biotechs is not a hack; it's someone accidentally deleting or overwriting a folder.

Offboarding checklist. When someone leaves, before their last day: transfer ownership of all their data to a designated team member, ensure all local data has been uploaded to the shared store, document any in-progress analyses, and revoke access credentials. This takes 30 minutes and prevents the scenario that opened this article.

What you don't need yet

The biotech data tooling ecosystem is full of solutions looking for problems. Here's what you should actively resist spending money on before Series A:

A data warehouse (Snowflake, BigQuery, Redshift). These are designed for companies that need to run complex analytical queries across terabytes of structured data. You have gigabytes of heterogeneous experimental data. A data warehouse at this stage is like buying a commercial kitchen to make toast. We've seen startups spend $50K+ annually on Snowflake contracts before they had enough structured data to fill a single table. The sales team was persuasive. The ROI was zero.

A BI tool (Tableau, Looker, Power BI). You have 8 scientists. They can make their own plots. When your leadership team needs dashboards to track 15 active programs across 3 therapeutic areas, you'll need BI. At 2 programs and 10 people, a well-formatted slide deck is your BI tool.

An ML platform (SageMaker, Vertex AI, Databricks). Unless ML is core to your discovery platform (you're a computational-first biotech), you don't need managed ML infrastructure. A scientist with a GPU instance and a well-organized Jupyter environment can do everything you need.

"Data mesh" or "data fabric" architecture. These are organizational patterns for companies with hundreds of data producers and consumers. You have one team in one room. Your data mesh is walking over to Sarah's desk and asking her about the ELISA results.

The common thread: these are all tools that solve coordination problems at scale. You don't have coordination problems at scale. You have a small team generating data that needs to be findable, reproducible, and secure. Solve that problem with simple tools, and you'll be in an excellent position to adopt more sophisticated infrastructure when you actually need it.

Cost breakdown

Here's what each approach actually costs for a typical pre-Series A biotech (5-15 people, 100-500 GB of data):

Approach	Setup cost	Monthly cost	Engineering time
DIY (this guide)	$0	~$200/mo	2 days initial + 2 hrs/month
Consultancy-assisted	$5-15K one-time	~$200/mo	Minimal ongoing
Enterprise platform	$10-25K setup	$4-5K/mo	Ongoing admin required

The DIY approach works if you have someone technical on your team who can dedicate two focused days to setting up S3, writing the naming convention doc, creating the catalog spreadsheet, and building the Docker environment. The consultancy-assisted approach makes sense when your team is all bench scientists and you want it done right, quickly, without pulling a scientist off their actual work. The enterprise platform approach makes sense after Series A when you have 30+ people, multiple programs, and regulatory requirements that demand validated systems.

Checklist: is your data stack ready for due diligence?

Investors are increasingly asking about data governance, especially for biotechs where the data is the asset. Before your next fundraise, make sure you can check every box:

1. All experimental data is stored in a centralized, backed-up cloud location — not on individual laptops or local drives.
2. Raw data is immutable. Original instrument outputs are preserved and never overwritten.
3. Every dataset has a corresponding catalog entry with metadata: who generated it, when, what experiment, what instrument.
4. Any computational analysis can be reproduced by a different team member using documented environments and pinned dependencies.
5. There is a clear folder structure and naming convention that the entire team follows consistently.
6. Access controls are in place: team members have appropriate permissions, and former employees have been offboarded.
7. Backups are automated and have been tested (you've actually tried restoring from a backup at least once).
8. There is a written offboarding procedure for data handoff when team members leave.
9. You can locate any dataset generated in the last 12 months within 5 minutes.
10. Your data practices are documented in a short (1-2 page) data governance policy that every team member has read.

If you checked 8 or more: you're ahead of 90% of pre-Series A biotechs. If you checked fewer than 5: you have a material risk that will surface at the worst possible time. The good news is that going from 3 to 8 takes a week of focused effort, not a six-month platform implementation.

↑ back to top